Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares were up 1.9% during mid-day trading on Wednesday . The stock traded as high as $6.86 and last traded at $6.80. Approximately 649,992 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 5,768,884 shares. The stock had previously closed at $6.67.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. Jefferies Financial Group reduced their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Tuesday, September 3rd. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Tuesday, September 3rd. KeyCorp dropped their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Finally, Needham & Company LLC cut their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating for the company in a research note on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $9.40.
Get Our Latest Stock Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Performance
The stock's fifty day simple moving average is $6.70 and its 200-day simple moving average is $7.82. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $1.67 billion, a PE ratio of -4.38 and a beta of 0.80.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million during the quarter, compared to analysts' expectations of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The business's revenue for the quarter was up 30.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.38) earnings per share. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current fiscal year.
Insider Transactions at Recursion Pharmaceuticals
In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $6.32, for a total value of $94,800.00. Following the sale, the chief financial officer now directly owns 1,426,506 shares of the company's stock, valued at approximately $9,015,517.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total transaction of $94,800.00. Following the sale, the chief financial officer now owns 1,426,506 shares in the company, valued at approximately $9,015,517.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the transaction, the director now directly owns 7,155,663 shares of the company's stock, valued at approximately $60,680,022.24. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 201,682 shares of company stock valued at $1,353,652 in the last 90 days. 15.75% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several hedge funds have recently modified their holdings of RXRX. ARK Investment Management LLC lifted its stake in shares of Recursion Pharmaceuticals by 14.5% during the second quarter. ARK Investment Management LLC now owns 28,142,918 shares of the company's stock valued at $211,072,000 after buying an additional 3,555,357 shares during the period. Baillie Gifford & Co. boosted its holdings in shares of Recursion Pharmaceuticals by 10.5% during the second quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company's stock worth $199,425,000 after purchasing an additional 2,522,132 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Recursion Pharmaceuticals by 2.2% in the first quarter. Vanguard Group Inc. now owns 16,014,764 shares of the company's stock valued at $159,667,000 after purchasing an additional 349,554 shares during the period. Kinnevik AB publ increased its stake in Recursion Pharmaceuticals by 14.4% in the second quarter. Kinnevik AB publ now owns 11,905,668 shares of the company's stock valued at $89,293,000 after purchasing an additional 1,500,000 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Recursion Pharmaceuticals by 12.6% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,362,803 shares of the company's stock worth $103,317,000 after buying an additional 1,159,023 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
